Published in N Engl J Med on July 21, 2005
Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med (2015) 3.57
Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res (2008) 3.05
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst (2010) 2.82
Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol (2012) 2.70
Model for individualized prediction of breast cancer risk after a benign breast biopsy. J Clin Oncol (2015) 2.25
Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol (2008) 2.06
Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. Breast J (2007) 1.84
Mammographic density, lobular involution, and risk of breast cancer. Br J Cancer (2008) 1.83
Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res (2010) 1.75
Nonradiation risk factors for thyroid cancer in the US Radiologic Technologists Study. Am J Epidemiol (2009) 1.74
Association between mammographic density and age-related lobular involution of the breast. J Clin Oncol (2010) 1.70
Benign breast disease--the risks of communicating risk. N Engl J Med (2005) 1.70
Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis. Radiology (2010) 1.62
SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium. Cancer Res (2008) 1.52
Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies. Cancer (2015) 1.47
p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res (Phila) (2011) 1.45
Clinical characteristics of breast cancers in African-American women with benign breast disease: a comparison to the surveillance, epidemiology, and end results program. Breast J (2014) 1.39
Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev (2008) 1.38
Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am J Pathol (2009) 1.35
A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control (2010) 1.35
Benign breast disease, mammographic breast density, and the risk of breast cancer. J Natl Cancer Inst (2013) 1.34
Mammary involution and breast cancer risk: transgenic models and clinical studies. J Mammary Gland Biol Neoplasia (2009) 1.32
Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat (2009) 1.25
Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol (2009) 1.23
Independent association of lobular involution and mammographic breast density with breast cancer risk. J Natl Cancer Inst (2010) 1.23
EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol (2011) 1.21
Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol (2010) 1.16
Risk factors for breast cancer from benign breast disease in a diverse population. Breast Cancer Res Treat (2008) 1.15
Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer. J Natl Cancer Inst (2014) 1.14
Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila) (2014) 1.13
Overexpression and hypomethylation of flap endonuclease 1 gene in breast and other cancers. Mol Cancer Res (2008) 1.10
Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression. Am J Pathol (2009) 1.07
DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell Death Dis (2014) 1.05
Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Res Treat (2011) 1.05
The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis. J Cancer Res Clin Oncol (2011) 1.03
Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer (2016) 1.02
Benign breast lesions in an African population: A 25-year histopathological review of 1864 cases. Niger Med J (2011) 1.02
Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ. Am J Surg (2006) 0.99
Sclerosing adenosis and risk of breast cancer. Breast Cancer Res Treat (2014) 0.99
Pseudoangiomatous stromal hyperplasia and breast cancer risk. Ann Surg Oncol (2010) 0.98
Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol (2014) 0.98
Risk factors for breast cancer in a black population--the Barbados National Cancer Study. Int J Cancer (2009) 0.96
Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. BMC Cancer (2006) 0.96
A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. Breast Cancer Res Treat (2008) 0.95
Breast lumps: a 21-year single-center clinical and histological analysis. Niger J Surg (2014) 0.94
Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues. Breast Cancer Res Treat (2011) 0.94
Nuclear nano-morphology markers of histologically normal cells detect the "field effect" of breast cancer. Breast Cancer Res Treat (2012) 0.93
Breast cancer risk accumulation starts early: prevention must also. Breast Cancer Res Treat (2014) 0.92
Predictors of perceived susceptibility of breast cancer and changes over time: a mixed modeling approach. Health Psychol (2008) 0.91
Estrogen metabolism and exposure in a genotypic-phenotypic model for breast cancer risk prediction. Cancer Epidemiol Biomarkers Prev (2011) 0.90
Making sense of cancer risk calculators on the web. J Gen Intern Med (2008) 0.89
Benign breast disease and the risk of subsequent breast cancer in African American women. Cancer Prev Res (Phila) (2012) 0.89
Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk. Cancer (2010) 0.89
Various types and management of breast cancer: an overview. J Adv Pharm Technol Res (2010) 0.88
Assessment of DNA methylation status in early stages of breast cancer development. Br J Cancer (2013) 0.88
Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer. Cancer Prev Res (Phila) (2011) 0.88
Exposure to bisphosphonates and risk of cancer: a protocol for nested case-control studies using the QResearch primary care database. BMJ Open (2012) 0.87
DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer. Clin Epigenetics (2015) 0.87
Benign proliferative breast diseases among female patients at a sub-Saharan Africa tertiary hospital: a cross sectional study. BMC Surg (2013) 0.86
Amping up estrogen receptors in breast cancer. Breast Cancer Res (2007) 0.86
Immune cell quantitation in normal breast tissue lobules with and without lobulitis. Breast Cancer Res Treat (2014) 0.86
Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment: findings from the Breast Cancer Surveillance Consortium. Cancer Epidemiol Biomarkers Prev (2009) 0.86
Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarkers Prev (2008) 0.86
Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women. Cancer Epidemiol Biomarkers Prev (2008) 0.86
Twenty-five years of breast cancer risk models and their applications. J Natl Cancer Inst (2015) 0.86
Mammotome(®) biopsy system for the resection of breast lesions: Clinical experience in two high-volume teaching hospitals. Exp Ther Med (2013) 0.85
Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer. World J Surg Oncol (2012) 0.85
YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention. Oncotarget (2011) 0.85
Predicting the future of genetic risk prediction. Cancer Epidemiol Biomarkers Prev (2011) 0.85
Hormonal and reproductive factors and risk of postmenopausal thyroid cancer in the NIH-AARP Diet and Health Study. Cancer Epidemiol (2011) 0.84
Flat epithelial atypia and risk of breast cancer: A Mayo cohort study. Cancer (2015) 0.84
Favorable modulation of benign breast tissue and serum risk biomarkers is associated with > 10 % weight loss in postmenopausal women. Breast Cancer Res Treat (2013) 0.84
Benign breast and gynecologic conditions, reproductive and hormonal factors, and risk of thyroid cancer. Cancer Prev Res (Phila) (2014) 0.84
Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women. Breast Cancer Res Treat (2007) 0.84
Estrogen effects on epithelial proliferation and benign proliferative lesions in the postmenopausal primate mammary gland. Lab Invest (2008) 0.84
Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer. Int J Cancer (2015) 0.83
Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program. Breast Cancer Res Treat (2014) 0.83
Low-fat dietary pattern and risk of benign proliferative breast disease: a randomized, controlled dietary modification trial. Cancer Prev Res (Phila) (2008) 0.83
Differential insulin-like growth factor II (IGF-II) expression: A potential role for breast cancer survival disparity. Growth Horm IGF Res (2010) 0.83
A comparison of hormonal profiles between breast cancer and benign breast disease: a case-control study. Ann Oncol (2013) 0.83
DNA repair gene variants associated with benign breast disease in high cancer risk women. Cancer Epidemiol Biomarkers Prev (2009) 0.82
Radial scars and subsequent breast cancer risk: results from the Nurses' Health Studies. Breast Cancer Res Treat (2013) 0.82
Benign breast disease and subsequent breast cancer: English record linkage studies. J Public Health (Oxf) (2010) 0.82
Novel molecular markers of malignancy in histologically normal and benign breast. Patholog Res Int (2011) 0.82
Preadolescent and adolescent risk factors for benign breast disease. J Adolesc Health (2013) 0.82
Mutations in the mitochondrial DNA D-loop region and breast cancer risk. Breast Cancer Res Treat (2009) 0.81
History of benign breast disease and risk of breast cancer among women in China: a case-control study. Cancer Causes Control (2008) 0.81
Do alterations in mitochondrial DNA play a role in breast carcinogenesis? J Oncol (2010) 0.81
Biologic characteristics of premalignant breast disease. Cancer Biomark (2010) 0.81
Natural history of age-related lobular involution and impact on breast cancer risk. Breast Cancer Res Treat (2016) 0.81
Biomarkers of dietary exposure are associated with lower risk of breast fibroadenomas in Chinese women. J Nutr (2010) 0.81
A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24. Cancer Epidemiol Biomarkers Prev (2012) 0.81
Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study. Breast Cancer Res Treat (2016) 0.81
Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women. Breast Cancer (Dove Med Press) (2011) 0.80
p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women. J Exp Clin Cancer Res (2010) 0.80
Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: a population-based cohort study. Breast Cancer Res Treat (2013) 0.80
The hormonal profile of benign breast disease. Br J Cancer (2012) 0.80
Risk factors for breast cancer in women biopsied for benign breast disease: a nested case-control study. Cancer Epidemiol (2010) 0.80
Affects of Anxiety and Depression on Health-Related Quality of Life among Patients with Benign Breast Lumps Diagnosed via Ultrasonography in China. Int J Environ Res Public Health (2015) 0.79
Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial. Breast Cancer Res (2014) 0.79
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Epidemiology and outcomes of osteoporotic fractures. Lancet (2002) 13.09
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. Am J Epidemiol (2011) 8.00
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc (2012) 6.54
Predictive value of BMD for hip and other fractures. J Bone Miner Res (2005) 6.46
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
Genetic variation and cancer: improving the environment for publication of association studies. Cancer Epidemiol Biomarkers Prev (2004) 6.24
Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clin Proc (2012) 6.21
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med (2005) 5.94
The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology (2008) 5.94
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA (2005) 5.52
Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst (2006) 5.12
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Nurse staffing and inpatient hospital mortality. N Engl J Med (2011) 4.51
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol (2012) 4.47
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med (2002) 4.18
Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol (2009) 4.13
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet (2009) 4.00
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol (2006) 3.81
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol (2010) 3.75
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
A reference standard for the description of osteoporosis. Bone (2007) 3.67
Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med (2015) 3.57
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Natural history of asymptomatic mitral valve prolapse in the community. Circulation (2002) 3.40
Why patients visit their doctors: assessing the most prevalent conditions in a defined American population. Mayo Clin Proc (2013) 3.40
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst (2002) 3.34
Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med (2004) 3.18
The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry (2005) 3.15
Trends in the mortality burden associated with diabetes mellitus: a population-based study in Rochester, Minn, 1970-1994. Arch Intern Med (2003) 3.13
Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol (2004) 3.11
Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res (2005) 3.11
Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc (2002) 3.09
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
Incidence of childhood distal forearm fractures over 30 years: a population-based study. JAMA (2003) 2.81
Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 2.81
A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res (2008) 2.76
Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology (2013) 2.73
Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res (2007) 2.71
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood (2003) 2.68
Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterology (2005) 2.64
Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA (2007) 2.62